BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dunaway Young S, Montes J, Kramer SS, Marra J, Salazar R, Cruz R, Chiriboga CA, Garber CE, De Vivo DC. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve 2016;54:836-42. [PMID: 27015431 DOI: 10.1002/mus.25120] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Rudnicki SA, Andrews JA, Duong T, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Genge A, Johnson NE, Tesi-Rocha C, Connolly AM, Darras BT, Felice K, Shieh PB, Mah JK, Statland J, Campbell C, Habib AA, Kuntz NL, Oskoui M, Day JW. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics. 2021;. [PMID: 33624184 DOI: 10.1007/s13311-020-01004-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
2 Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, Grandis M, Trojsi F, Cerri F, Ferraro M, Bozzoni V, Caumo L, Piras R, Tanel R, Saccani E, Meneri M, Vacchiano V, Ricci G, Soraru' G, D'Errico E, Tramacere I, Bortolani S, Pavesi G, Zanin R, Silvestrini M, Politano L, Schenone A, Previtali SC, Berardinelli A, Turri M, Verriello L, Coccia M, Mantegazza R, Liguori R, Filosto M, Marrosu G, Siciliano G, Simone IL, Mongini T, Comi G, Pegoraro E. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 2020;91:1166-74. [PMID: 32917822 DOI: 10.1136/jnnp-2020-323822] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 21.5] [Reference Citation Analysis]
3 Chabanon A, Seferian AM, Daron A, Péréon Y, Cances C, Vuillerot C, De Waele L, Cuisset JM, Laugel V, Schara U, Gidaro T, Gilabert S, Hogrel JY, Baudin PY, Carlier P, Fournier E, Lowes LP, Hellbach N, Seabrook T, Toledano E, Annoussamy M, Servais L; NatHis-SMA study group. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. PLoS One 2018;13:e0201004. [PMID: 30048507 DOI: 10.1371/journal.pone.0201004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 14.0] [Reference Citation Analysis]
4 Chiriboga CA, Marra J, LaMarca NM, Young SD, Weimer LH, Levin B, McCabe B. Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients. Neuromuscul Disord 2020;30:693-700. [PMID: 32788051 DOI: 10.1016/j.nmd.2020.07.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Stępień A, Jędrzejowska M, Guzek K, Rekowski W, Stępowska J. Reliability of four tests to assess body posture and the range of selected movements in individuals with spinal muscular atrophy. BMC Musculoskelet Disord 2019;20:54. [PMID: 30732590 DOI: 10.1186/s12891-018-2389-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pechmann A, König K, Bernert G, Schachtrup K, Schara U, Schorling D, Schwersenz I, Stein S, Tassoni A, Vogt S, Walter MC, Lochmüller H, Kirschner J. SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J Rare Dis 2019;14:18. [PMID: 30665421 DOI: 10.1186/s13023-019-0998-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
7 McMillan HJ. Nusinersen: Evidence of sustained clinical improvement and lessened fatigue in older ambulatory patients with spinal muscular atrophy. Muscle Nerve 2020;61:1-2. [PMID: 31599453 DOI: 10.1002/mus.26735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Kizina K, Stolte B, Totzeck A, Bolz S, Schlag M, Ose C, von Velsen O, Kleinschnitz C, Hagenacker T. Fatigue in adults with spinal muscular atrophy under treatment with nusinersen. Sci Rep 2020;10:11069. [PMID: 32632203 DOI: 10.1038/s41598-020-68051-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, Xia S, Bennett CF, Bishop KM, Shefner JM, Green AM, Sun P, Bhan I, Gheuens S, Schneider E, Farwell W, De Vivo DC;  ISIS-396443-CS2/ISIS-396443-CS12 Study Groups. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies. Neurology. 2019;92:e2492-e2506. [PMID: 31019106 DOI: 10.1212/wnl.0000000000007527] [Cited by in Crossref: 85] [Cited by in F6Publishing: 41] [Article Influence: 28.3] [Reference Citation Analysis]
10 Smeriglio P, Langard P, Querin G, Biferi MG. The Identification of Novel Biomarkers Is Required to Improve Adult SMA Patient Stratification, Diagnosis and Treatment. J Pers Med 2020;10:E75. [PMID: 32751151 DOI: 10.3390/jpm10030075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
11 Bartels B, de Groot JF, Habets LE, Wijngaarde CA, Vink W, Stam M, Asselman FL, van Eijk RPA, van der Pol WL. Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests. Orphanet J Rare Dis 2020;15:75. [PMID: 32293503 DOI: 10.1186/s13023-020-1348-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Pons C, Barrière A, Bertrand G, Morard MD, Lilien C, Vuillerot C. [French adaptation of motor function scales for patients with spinal muscular atrophy]. Med Sci (Paris) 2019;35 Hors série n° 2:24-8. [PMID: 31859627 DOI: 10.1051/medsci/2019189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Binz C, Schreiber-Katz O, Kumpe M, Ranxha G, Siegler H, Wieselmann G, Petri S, Osmanovic A. An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment. J Neurol 2021;268:950-62. [PMID: 33029682 DOI: 10.1007/s00415-020-10227-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Gavriilaki M, Moschou M, Papaliagkas V, Notas K, Chatzikyriakou E, Papagiannopoulos S, Arnaoutoglou M, Kimiskidis VK. Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis. Neurotherapeutics 2022. [PMID: 35178673 DOI: 10.1007/s13311-022-01200-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Salazar R, Montes J, Dunaway Young S, McDermott MP, Martens W, Pasternak A, Quigley J, Mirek E, Glanzman AM, Civitello M, Gee R, Duong T, Mazzone ES, Main M, Mayhew A, Ramsey D, Muni Lofra R, Coratti G, Fanelli L, De Sanctis R, Forcina N, Chiriboga C, Darras BT, Tennekoon GI, Scoto M, Day JW, Finkel R, Muntoni F, Mercuri E, De Vivo DC. Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function. Pediatr Phys Ther. 2018;30:209-215. [PMID: 29924070 DOI: 10.1097/pep.0000000000000515] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Montes J, Zanotto D, Dunaway Young S, Salazar R, De Vivo DC, Agrawal S. Gait assessment with solesound instrumented footwear in spinal muscular atrophy: SoleSound Gait Assessment in SMA. Muscle Nerve 2017;56:230-6. [DOI: 10.1002/mus.25484] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
17 Montes J, Goodwin AM, McDermott MP, Uher D, Hernandez FM, Coutts K, Cocchi J, Hauschildt M, Cornett KM, Rao AK, Monani UR, Ewing Garber C, De Vivo DC. Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy. Ann Clin Transl Neurol 2021;8:1086-95. [PMID: 33788421 DOI: 10.1002/acn3.51353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Querin G, Lenglet T, Debs R, Stojkovic T, Behin A, Salachas F, Le Forestier N, Amador MDM, Bruneteau G, Laforêt P, Blancho S, Marchand-Pauvert V, Bede P, Hogrel JY, Pradat PF. Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study. J Neurol 2021;268:1792-802. [PMID: 33388927 DOI: 10.1007/s00415-020-10332-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Jochmann E, Steinbach R, Jochmann T, Chung HY, Rödiger A, Neumann R, Mayer TE, Kirchhof K, Loudovici-Krug D, Smolenski UC, Witte OW, Grosskreutz J. Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen. Ther Adv Neurol Disord 2020;13:1756286420907803. [PMID: 32180828 DOI: 10.1177/1756286420907803] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
20 Querin G, Bede P, Marchand-Pauvert V, Pradat PF. Biomarkers of Spinal and Bulbar Muscle Atrophy (SBMA): A Comprehensive Review. Front Neurol 2018;9:844. [PMID: 30364135 DOI: 10.3389/fneur.2018.00844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
21 Pitarch Castellano I, Cabrera-serrano M, Calvo Medina R, Cattinari M, Espinosa García S, Fernández-ramos J, García Campos O, Gómez-andrés D, Grimalt Calatayud M, Gutiérrez Martínez A, Ibáñez Albert E, Kapetanovic García S, Madruga-garrido M, Martínez-moreno M, Medina Cantillo J, Melián Suárez A, Moreno Escribano A, Munell F, Nascimento Osorio A, Pascual-pascual S, Povedano M, Santana Casiano I, Vázquez-costa J. Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus). Neurología (English Edition) 2022. [DOI: 10.1016/j.nrleng.2021.07.002] [Reference Citation Analysis]
22 Pera MC, Luigetti M, Sivo S, Lapenta L, Granata G, Antonaci L, Coratti G, Forcina N, Pane M, Mercuri E. Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? Neuromuscul Disord 2018;28:863-4. [PMID: 30177455 DOI: 10.1016/j.nmd.2018.07.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
23 de Valle K, Dobson F, Woodcock I, Carroll K, Ryan MM, Heatwole C, Eichinger K, McGinley JL. Reliability and validity of the FSHD-composite outcome measure in childhood facioscapulohumeral dystrophy. Neuromuscul Disord 2021;31:706-15. [PMID: 34210539 DOI: 10.1016/j.nmd.2021.05.011] [Reference Citation Analysis]
24 Nelson LL, Iannaccone ST. Clinical outcome assessments in Duchenne muscular dystrophy and spinal muscular atrophy: past, present and future. Neuromuscul Disord 2021;31:1028-37. [PMID: 34412961 DOI: 10.1016/j.nmd.2021.07.015] [Reference Citation Analysis]
25 Phillips D, Tomazos IC, Moseley S, L'Italien G, Gomes da Silva H, Lerma Lara S. Reliability and Validity of the 6-Minute Walk Test in Hypophosphatasia. JBMR Plus 2019;3:e10131. [PMID: 31346563 DOI: 10.1002/jbm4.10131] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
26 Rastelli E, Montagnese F, Massa R, Schoser B. Towards clinical outcome measures in myotonic dystrophy type 2: a systematic review. Current Opinion in Neurology 2018;31:599-609. [DOI: 10.1097/wco.0000000000000591] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
27 Montes J, Dunaway Young S, Mazzone ES, Pasternak A, Glanzman AM, Finkel RS, Darras BT, Muntoni F, Mercuri E, De Vivo DC, Bishop KM, Schneider E, Bennett CF, Foster R, Farwell W; CS2 and CS12 Study Groups. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve 2019;60:409-14. [PMID: 31298747 DOI: 10.1002/mus.26633] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
28 Hiebeler M, Abicht A, Reilich P, Walter MC. Effect of Discontinuation of Nusinersen Treatment in Long-Standing SMA3. J Neuromuscul Dis 2021;8:537-42. [PMID: 33682724 DOI: 10.3233/JND-210644] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Spina E, Topa A, Iodice R, Tozza S, Ruggiero L, Dubbioso R, Esposito M, Dolce P, Santoro L, Manganelli F. Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP. J Neurol 2019;266:860-5. [PMID: 30721354 DOI: 10.1007/s00415-019-09207-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
30 Montes J, McDermott MP, Mirek E, Mazzone ES, Main M, Glanzman AM, Duong T, Young SD, Salazar R, Pasternak A, Gee R, De Sanctis R, Coratti G, Forcina N, Fanelli L, Ramsey D, Milev E, Civitello M, Pane M, Pera MC, Scoto M, Day JW, Tennekoon G, Finkel RS, Darras BT, Muntoni F, De Vivo DC, Mercuri E. Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. PLoS One 2018;13:e0199657. [PMID: 29944707 DOI: 10.1371/journal.pone.0199657] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
31 Shefner JM. Strength Testing in Motor Neuron Diseases. Neurotherapeutics 2017;14:154-60. [PMID: 27600518 DOI: 10.1007/s13311-016-0472-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
32 Elsheikh B, Severyn S, Zhao S, Kline D, Linsenmayer M, Kelly K, Tellez M, Bartlett A, Heintzman S, Reynolds J, Sterling G, Weaver T, Rajneesh K, Kolb SJ, Arnold WD. Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA. Front Neurol 2021;12:650535. [PMID: 34093395 DOI: 10.3389/fneur.2021.650535] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Lenzoni S, Semenza C, Calligaro D, Turcano P, Caumo L, Pegoraro E, Wennberg A. Cognitive profiles and clinical factors in type III Spinal Muscular Atrophy: a preliminary study. Neuromuscular Disorders 2022. [DOI: 10.1016/j.nmd.2022.05.005] [Reference Citation Analysis]
34 Stefanetti RJ, Blain A, Jimenez-Moreno C, Errington L, Ng YS, McFarland R, Turnbull DM, Newman J, Gorman GS. Measuring the effects of exercise in neuromuscular disorders: a systematic review and meta-analyses. Wellcome Open Res 2020;5:84. [PMID: 32671231 DOI: 10.12688/wellcomeopenres.15825.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Matsumaru N, Hattori R, Ichinomiya T, Tsukamoto K, Kato Z. New quantitative method for evaluation of motor functions applicable to spinal muscular atrophy. Brain Dev 2018;40:172-80. [PMID: 29395660 DOI: 10.1016/j.braindev.2017.12.003] [Reference Citation Analysis]
36 Chiriboga CA. Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother 2017;17:955-62. [PMID: 28884620 DOI: 10.1080/14737175.2017.1364159] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
37 Wataya T, Takasaki S, Hoshino M, Makioka H, Nakamura G, Matsuda N. Real-world safety of nusinersen in Japan: results from an interim analysis of a post-marketing surveillance and safety database. Int J Neurosci 2021;:1-13. [PMID: 34809526 DOI: 10.1080/00207454.2021.1995382] [Reference Citation Analysis]
38 Mancuso M, McFarland R, Klopstock T, Hirano M; consortium on Trial Readiness in Mitochondrial Myopathies. International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy. Neuromuscul Disord 2017;27:1126-37. [PMID: 29074296 DOI: 10.1016/j.nmd.2017.08.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
39 Fragala-Pinkham M, Pasternak A, McDermott MP, Mirek E, Glanzman AM, Montes J, Dunaway Young S, Salazar R, Quigley J, Riley SO, Chiriboga CA, Finkel RS, Tennekoon G, Martens WB, De Vivo DC, Darras BT. Psychometric properties of the PEDI-CAT for children and youth with spinal muscular atrophy. J Pediatr Rehabil Med 2021. [PMID: 34275913 DOI: 10.3233/PRM-190664] [Reference Citation Analysis]
40 Pierzchlewicz K, Kępa I, Podogrodzki J, Kotulska K. Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment. Child Neurol Open 2021;8:2329048X211008725. [PMID: 33997096 DOI: 10.1177/2329048X211008725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Rodriguez-Torres R, Fabiano J, Goodwin A, Rao AK, Kinirons S, De Vivo D, Montes J. Neuroanatomical Models of Muscle Strength and Relationship to Ambulatory Function in Spinal Muscular Atrophy. J Neuromuscul Dis 2020;7:459-66. [PMID: 32925091 DOI: 10.3233/JND-200550] [Reference Citation Analysis]
42 Montagnese F, Rastelli E, Khizanishvili N, Massa R, Stahl K, Schoser B. Validation of Motor Outcome Measures in Myotonic Dystrophy Type 2. Front Neurol 2020;11:306. [PMID: 32373059 DOI: 10.3389/fneur.2020.00306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Dunaway Young S, Montes J, Kramer SS, Podwika B, Rao AK, De Vivo DC. Perceived Fatigue in Spinal Muscular Atrophy: A Pilot Study. J Neuromuscul Dis 2019;6:109-17. [PMID: 30562906 DOI: 10.3233/JND-180342] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
44 De Wel B, De Schaepdryver M, Poesen K, Claeys KG. Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months. Ann Clin Transl Neurol 2022. [PMID: 35833245 DOI: 10.1002/acn3.51625] [Reference Citation Analysis]
45 Savini G, Asteggiano C, Paoletti M, Parravicini S, Pezzotti E, Solazzo F, Muzic SI, Santini F, Deligianni X, Gardani A, Germani G, Farina LM, Bergsland N, Gandini Wheeler-Kingshott CAM, Berardinelli A, Bastianello S, Pichiecchio A. Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment? Front Neurol 2021;12:613834. [PMID: 33854470 DOI: 10.3389/fneur.2021.613834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Müschen LH, Osmanovic A, Binz C, Jendretzky KF, Ranxha G, Bronzlik P, Abu-Fares O, Wiehler F, Möhn N, Hümmert MW, Gingele S, Götz F, Stangel M, Skripuletz T, Schreiber-Katz O, Petri S. Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients. Brain Sci 2021;11:296. [PMID: 33652830 DOI: 10.3390/brainsci11030296] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
47 Alfano LN, Iammarino MA, Reash NF, Powers BR, Shannon K, Connolly AM, Waldrop MA, Noritz GH, Shell R, Tsao CY, Flanigan KM, Mendell JR, Lowes LP. Validity and Reliability of the Neuromuscular Gross Motor Outcome. Pediatr Neurol 2021;122:21-6. [PMID: 34271497 DOI: 10.1016/j.pediatrneurol.2021.05.021] [Reference Citation Analysis]
48 Szabó L, Gergely A, Jakus R, Fogarasi A, Grosz Z, Molnár MJ, Andor I, Schulcz O, Goschler Á, Medveczky E, Czövek D, Herczegfalvi Á. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients. Eur J Paediatr Neurol 2020;27:37-42. [PMID: 32456992 DOI: 10.1016/j.ejpn.2020.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
49 Bartels B, Habets LE, Stam M, Wadman RI, Wijngaarde CA, Schoenmakers MAGC, Takken T, Hulzebos EHJ, van der Pol WL, de Groot JF. Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests. BMC Neurol 2019;19:21. [PMID: 30738436 DOI: 10.1186/s12883-019-1244-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
50 Montgomery G, McPhee J, Pääsuke M, Sipilä S, Maier AB, Hogrel JY, Degens H. Determinants of Performance in the Timed Up-and-Go and Six-Minute Walk Tests in Young and Old Healthy Adults. J Clin Med 2020;9:E1561. [PMID: 32455757 DOI: 10.3390/jcm9051561] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Elgestad Stjernfeldt P, Sjögren P, Wårdh I, Boström AM. Systematic review of measurement properties of methods for objectively assessing masticatory performance. Clin Exp Dent Res 2019;5:76-104. [PMID: 30847236 DOI: 10.1002/cre2.154] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
52 Yeo CJJ, Simeone SD, Townsend EL, Zhang RZ, Swoboda KJ. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy. J Neuromuscul Dis 2020;7:257-68. [PMID: 32333595 DOI: 10.3233/JND-190453] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 20.0] [Reference Citation Analysis]
53 Nance JR. Spinal Muscular Atrophy. Continuum (Minneap Minn) 2020;26:1348-68. [PMID: 33003005 DOI: 10.1212/CON.0000000000000918] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Milella G, Introna A, D'Errico E, Fraddosio A, Scaglione G, Morea A, Ucci M, Ruggieri M, Mastrapasqua M, Megna M, Puntillo F, Simone IL. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience. Clin Drug Investig 2021;41:775-84. [PMID: 34389971 DOI: 10.1007/s40261-021-01071-0] [Reference Citation Analysis]
55 Pera MC, Coratti G, Bovis F, Pane M, Pasternak A, Montes J, Sansone VA, Dunaway Young S, Duong T, Messina S, Mizzoni I, D'Amico A, Civitello M, Glanzman AM, Bruno C, Salmin F, Morando S, De Sanctis R, Sframeli M, Antonaci L, Frongia AL, Rohwer A, Scoto M, De Vivo DC, Darras BT, Day J, Martens W, Patanella KA, Bertini E, Muntoni F, Finkel R, Mercuri E; iSMAC group. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. Ann Clin Transl Neurol 2021;8:1622-34. [PMID: 34165911 DOI: 10.1002/acn3.51411] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Stolte B, Bois J, Bolz S, Kizina K, Totzeck A, Schlag M, Kleinschnitz C, Hagenacker T. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy. Eur J Neurol 2020;27:2586-94. [DOI: 10.1111/ene.14472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Veerapandiyan A, Eichinger K, Guntrum D, Kwon J, Baker L, Collins E, Ciafaloni E. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience. Muscle Nerve 2020;61:222-6. [PMID: 31773738 DOI: 10.1002/mus.26769] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
58 Hodgkinson VL, Oskoui M, Lounsberry J, M'Dahoma S, Butler E, Campbell C, MacKenzie A, McMillan HJ, Simard L, Vajsar J, Brais B, Chapman KM, Chrestian N, Crone M, Dobrowolski P, Dojeiji S, Dowling JJ, Dupré N, Genge A, Gonorazky H, Hasal S, Izenberg A, Johnston W, Leung E, Lochmüller H, Mah JK, Marerro A, Massie R, McAdam L, McCormick A, Melanson M, Mezei MM, Nguyen CE, O'Connell C, O'Ferrall EK, Pfeffer G, Phan C, Plamondon S, Poulin C, Rodrigue X, Schellenberg KL, Selby K, Sheriko J, Shoesmith C, Smith G, Taillon M, Taylor S, Warman Chardon J, Worley S, Korngut L. A National Spinal Muscular Atrophy Registry for Real-World Evidence. Can J Neurol Sci 2020;47:810-5. [PMID: 32493524 DOI: 10.1017/cjn.2020.111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Bartels B, Montes J, van der Pol WL, de Groot JF. Physical exercise training for type 3 spinal muscular atrophy. Cochrane Database Syst Rev 2019;3:CD012120. [PMID: 30821348 DOI: 10.1002/14651858.CD012120.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
60 Vuillerot C. State of the art for motor function assessment tools in spinal muscular atrophy (SMA). Arch Pediatr 2020;27:7S40-4. [PMID: 33357597 DOI: 10.1016/S0929-693X(20)30276-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Mendonça RH, Polido GJ, Matsui C, Silva AM, Solla DJ, Reed UC, Zanoteli E. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience. JND 2021;8:101-8. [DOI: 10.3233/jnd-200551] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Binz C, Osmanovic A, Thomas NH, Stolte B, Freigang M, Cordts I, Griep R, Uzelac Z, Wurster CD, Kamm C, Siegler HA, Wieselmann G, Hermann A, Lingor P, Deschauer M, Ludolph AC, Meyer T, Günther R, Hagenacker T, Petri S, Schreiber-Katz O. Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy. Ann Clin Transl Neurol 2022. [PMID: 35191616 DOI: 10.1002/acn3.51520] [Reference Citation Analysis]
63 Goodwin AM, Cornett KMD, McKay MJ, Burns J, Garber CE, De Vivo DC, Montes J. Limitations of 6-minute walk test reference values for spinal muscular atrophy. Muscle Nerve 2020;61:375-82. [PMID: 31884700 DOI: 10.1002/mus.26794] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]